NASDAQ - Clovis Oncology, Inc.

График котировок Clovis Oncology, Inc.

Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 3.87
EBITDA -0.32
Цена ао 6.01



Название Значение Оценка
P/S 3.87 2
P/BV 0
P/E 0
EV/EBITDA -3.12 10


Название Значение Оценка
ROA, % -31.38 1
ROE, % 0


Название Значение Оценка
Div yield, % 0
DSI 0 0


Название Значение Оценка

Импульс роста

Название Значение Оценка
Рост прибыли, % -4.25 0
Рост цены акции, % -214.08 0
Рост дивидендов, % 0 0

Основные владельцы

Institutions Объем Доля, %
Healthcare Value Capital LLC 250000 0.24
SSGA Funds Management Inc 20834600 20.14
Hennion & Walsh, Inc 400 0
ETFS Management (AUS) Ltd 51483 0.05
Palo Alto Investors, LLC 4469411 4.32
Harbor Capital Advisors Inc 290272 0.28
Pharus Asset Management SA 26600 0.03
First Trust Portfolios L.P. 12829 0.01
E Fund Mgmt Co.,Ltd 20126 0.02
Psagot Mutual Funds Ltd 2000 0
Candriam Belgium 1154260 1.12
State Street Global Advisors 964226 0.93
Lyxor International Asset Management S.A.S. 226233 0.22
Diem Client Partner AG 11500 0.01
Private Wealth Advisors, LLC 151297 0.15
Gamco Asset Management Inc 99000 0.1
Principal Global Investors, LLC 331214 0.32
Armistice Capital, LLC 1848000 1.79
Fidelity Management & Research Company LLC 2078283 2.01
Ikarian Capital, LLC 756236 0.73

Содержится в ETF

ETF Доля, % Доходность за год, %
Direxion Daily S&P Biotech Bull 3x Shares 0.81 154.26
SPDR S&P Biotech ETF 1.14 60.93

Похожие компании

Описание Clovis Oncology, Inc.

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It also provides lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors, platelet-derived growth factor receptors alpha and beta, and fibroblast growth factor receptors. The company distributes its products primarily through specialty distributors and pharmacy providers to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, and Advenchen Laboratories LLC; collaboration agreements with Bristol-Myers Squibb Company and Myriad Genetics, Inc.; and a partnership with Foundation Medicine, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.